Skip to content
Screener

UroGen Pharma URGN Operating Income

Discontinued — last reported Q2 '21

Operating Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$7.14B+7.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$69.79M-8.3%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
-$34.87M-20.1%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
-$42M-31.9%
CG Oncology logo
CG OncologyCGON
-$86.4M-77.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$75M+30.6%

Other financials

Income statement

See full
Revenue$72.5M+199%
Net income-$14.4M+71.3%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$197.5M+55.0%
Total equity-$132.4M-41.8%
Total assets$252.6M+21.0%

Cash flow

See full
Operating cash flow-$33.0M+17.1%
CapEx$60.0K-57.4%
Free cash flow-$33.1M+17.3%

Valuation

See full
Market cap$2.22B+140%
Enterprise value$2.34B+144%
P/S11.8×+2.0×

Profitability

See full
Gross margin89.7%—
Operating margin-329.7%—
Net margin-51.7%-21.0pp
FCF margin-84.3%-22.2pp

Returns & leverage

See full
Return on equity-211.6%—
Debt / equity4.8×—
Current ratio3.8×-0.3×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: UroGen Pharma’s 10-Q, filed August 4, 2021. Open the filing →

Filed
Aug 4, 2021, 8:09 AM EDT
Fiscal quarter
Q2 FY2021
Calendar quarter
Q2 2021
Accession
0001564590-21-040510

FAQ

What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.